ClinicalTrials.gg
RecruitingNCT07207200Updated Oct 9, 2026

Impact of Morning Light Therapy in IBD

An interventional study of Morning Light Therapy in Inflammatory Bowel Disease, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 9, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai — 2 open to participants now, 3 under way, none of them phase 3. Inflammatory Bowel Diseases · Icahn School of Medicine at Mount Sinai.

Started
2026
the only one that year
No phase
5 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai, this one is the only one that started in 2026, is one of 5 with no phase, and was the 11th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

2 of the 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai, or all of them as a file.
02

Study summary

The pilot study will focus on the effects of morning light therapy (MLT) in adult patients with ulcerative colitis (UC) who have evidence of poor sleep quality and active inflammation. The specific population is at risk for circadian rhythm sleep-wake disorders and has significant potential benefit from circadian realignment, which may lead to improved sleep quality and, ultimately, UC-related inflammatory activity. During an initial one-week lead-in period, participants will obtain baseline circadian-related labs, complete symptom-related surveys, and use a wearable device continuously to obtain baseline sleep-wake data. After the lead-in week, patients will undergo one hour of MLT while wearing wearable devices continuously and completing daily symptom surveys. At the end of four weeks of MLT, patients will obtain post-intervention circadian and inflammatory assessments in addition to completing the same symptom-related surveys.

03

Conditions studied

  • Inflammatory Bowel Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with ulcerative colitis and signs of inflammation (Fecal calprotectin >150 mcg/g and/or CRP >5)

Exclusion criteria

Exclusion Criteria:

  • Known pregnancy or currently lactating women
  • Current or active treatment for previously diagnosed malignancy. Patients with squamous and basal cell cancer of the skin are eligible for the study.
  • Serious co-morbidity including: Immunodeficiency, recent myocardial infarction or stroke, history of renal or hepatic failure, infection such as abscess, opportunistic infection, or sepsis.
  • Patients with pacemaker or defibrillators
  • The use of medications known to affect autonomic nervous system function, including but not limited to beta-blockers and benzodiazepines.
  • Comprehension of the English language not adequate to understand the questionnaires
  • Recent changes in IBD directed therapies within the last 3 months
  • Regular use of antidiarrheal agents.
  • Regular use of medications that have been shown to impair sleep (e.g. , stimulants). If willing (and medically appropriate) to for 4 weeks, participant can be then enrolled in the study
  • Regular use of sleep medications including but not limited to: benzodiazepine hypnotics, non-benzodiazepine hypnotics, antipsychotics, and melatonin. If willing (and medically appropriate) to washout for 4 weeks, participant can be then enrolled in the study
  • Patients with prior colectomy or total proctocolectomy
  • History of any surgery within 3 months
  • Untreated Obstructive Sleep Apnea
  • Blindness or severely impaired, uncorrected vision
  • Employment which includes nocturnal shift work
  • Traveling multiple time zones within the study time frame
  • Any marijuana or illicit drugs use within one month of enrollment or ongoing basis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Adult patients with Ulcerative Colitis (UC)

    Adult patients with ulcerative colitis (UC)

    Device: Morning Light Therapy

Interventions

  • DeviceMorning Light Therapy

    One hour of morning light therapy each day for four weeks

06

What researchers measure

Primary outcomes

  1. C-reactive protein (CRP) level

    C-reactive protein (CRP) is produced by the liver. The CRP test is a general test to check for inflammation in the body.

    Time frame: week 4

  2. Fecal Calprotectin (FCP)

    The fecal calprotectin is a stool test which measures intestinal inflammation.

    Time frame: week 4

Secondary outcomes

  1. Patient-Reported Outcomes Measurement Information System (PROMIS 10)

    A series of person-centered measures that evaluate and monitor physical, mental, and social health in adults.

    Time frame: week 4

  2. Change in Microbiome composition

    Microbiome assessment

    Time frame: week 4

  3. Change in Morning urine melatonin level

    Urine samples at the beginning and end of the study

    Time frame: week 4

07

Study locations

1 of 1 sites recruiting
  • Mount Sinai Hospital
    New York, New York 10029, United States
    Recruiting
    • Hyder Said · Contact212-824-7786
    • Hyder Said · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — There is no IRB approval to share individual patient data

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 12 months is below that.

Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Jul 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Oct 3, 2025
StartActual
Jul 1, 2026was Mar 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 2026→Jul 1, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Start date Mar 2026→Jul 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07207200
Responsible party
Robert Hirten (Associate Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Oct 3, 2025
Start date
Jul 1, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Hyder Said
Contact
hyder.said@mountsinai.org
212-824-7786
Hyder Said
principal investigator · Icahn School of Medicine at Mount Sinai
Robert Hirten, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion